CDK4 and non-small cell lung carcinoma: Finally, our previous study utilizing the simplified interventional point matching system (SIMS), based on transcriptomic/genomic analysis of matched tumor and normal biopsies, yielded the anti‐PD‐L1/anti‐VEGFR/‐CDK4/6 inhibitor triplet combination as possibly affecting a significant subset of patients with NSCLC (9).